9342-8530 Québec Inc.
DGCRF
$0.00
$0.000.00%
| Weiss Ratings | DGCRF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Unrated | |||
| Risk Index | Unrated | |||
| Risk Grade | U | |||
| Reward Grade | U | |||
| Rating Factors | DGCRF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | Unrated | |||
| Growth Index | Unrated | |||
| Efficiency Index | Unrated | |||
| Solvency Index | Unrated | |||
| Total Return Index | Unrated | |||
| Volatility Index | Unrated | |||
| Beta / Standard Deviation | DGCRF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -47.02 | |||
| Price History | DGCRF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -- | |||
| 30-Day Total Return | -- | |||
| 60-Day Total Return | -- | |||
| 90-Day Total Return | -- | |||
| Year to Date Total Return | -- | |||
| 1-Year Total Return | -- | |||
| 2-Year Total Return | -- | |||
| 3-Year Total Return | -99.90% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | 0.00% | |||
| 52-Week Low % Change | 0.00% | |||
| Price | DGCRF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.00 | |||
| 52-Week Low Price | $0.00 | |||
| 52-Week Low Price (Date) | Apr 12, 2024 | |||
| 52-Week High Price (Date) | Apr 12, 2024 | |||
| Valuation | DGCRF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 43.00 | |||
| Enterprise Value | -- | |||
| Price/Earnings (TTM) | 0.00 | |||
| Earnings Per Share (TTM) | 0.05 | |||
| Earnings Per Share Growth | -248.75% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.00 | |||
| Price/Book (Q) | 0.00 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.00 | |||
| Enterprise Value/EBITDA (TTM) | -- | |||
| Enterprise Value/EBIT | -- | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | DGCRF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 43.04M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | $0.09 | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | $0.09 | |||
| Company Info | DGCRF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 418-527-6100 | |||
| Address | 4535 Wilfrid-Hamel Boulevard Quebec, QC G1P 2J7 | |||
| Website | www.diagnocure.com | |||
| Country | Canada | |||
| Year Founded | 1994 | |||
| Profitability | DGCRF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 74.36% | |||
| Profit Margin | 40.83% | |||
| Management Effectiveness | DGCRF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 127.12% | |||
| Return on Equity | 124.77% | |||
| Income Statement | DGCRF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 5.01M | |||
| Total Revenue (TTM) | 5.03M | |||
| Revenue Per Share | $0.12 | |||
| Gross Profit (TTM) | 5.02M | |||
| EBITDA (TTM) | 3.98M | |||
| EBIT (TTM) | 3.74M | |||
| Net Income (TTM) | 2.05M | |||
| Net Income Avl. to Common (TTM) | 2.05M | |||
| Total Revenue Growth (Q YOY) | -66.51% | |||
| Earnings Growth (Q YOY) | 23.89% | |||
| EPS Diluted (TTM) | 0.05 | |||
| EPS Diluted Growth (Q YOY) | 23.53% | |||
| Balance Sheet | DGCRF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 301.20K | |||
| Cash Per Share (Q) | $0.01 | |||
| Total Current Assets (Q) | 386.50K | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 308.00K | |||
| Current Ratio (Q) | 3.738 | |||
| Book Value Per Share (Q) | $0.01 | |||
| Total Assets (Q) | 411.40K | |||
| Total Current Liabilities (Q) | 103.40K | |||
| Total Debt (Q) | 0.00 | |||
| Total Liabilities (Q) | 103.40K | |||
| Total Common Equity (Q) | 308.00K | |||
| Cash Flow | DGCRF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 501.70K | |||
| Cash from Financing (TTM) | -20.70K | |||
| Net Change in Cash (TTM) | -331.20K | |||
| Levered Free Cash Flow (TTM) | 2.61M | |||
| Cash from Operations (TTM) | -812.20K | |||
